Overview of the Experimental Physics and Industrial Control System (EPICS) Channel Archiver

The Channel Archiver has been operational for more than two years at Los Alamos National Laboratory and other sites. This paper introduces the available components (data sampling engine, viewers, scripting interface, HTTP/CGI integration and data management), presents updated performance measurements and reviews operational experience with the Channel Archiver.Comment: 3 pages, 1 figure, 8th International Conference on Accelerator and Large Experimental Physics Control Systems (PSN THAP019), San Jose, CA, USA, November 27-3

Integrating LabVIEW into a Distributed Computing Environment

Being easy to learn and well suited for a self-contained desktop laboratory setup, many casual programmers prefer to use the National Instruments LabVIEW environment to develop their logic. An ActiveX interface is presented that allows integration into a plant-wide distributed environment based on the Experimental Physics and Industrial Control System (EPICS). This paper discusses the design decisions and provides performance information, especially considering requirements for the Spallation Neutron Source (SNS) diagnostics system.Comment: 3 pages, 2 figures, 8th International Conference on Accelerator and Large Experimental Physics Control Systems (PSN THAP032), San Jose, CA, USA, November 27-3

The EPICS Software Framework Moves from Controls to Physics

The Experimental Physics and Industrial Control System (EPICS), is an open-source software framework for high-performance distributed control, and is at the heart of many of the world’s large accelerators and telescopes. Recently, EPICS has undergone a major revision, with the aim of better computing supporting for the next generation of machines and analytical tools. Many new data types, such as matrices, tables, images, and statistical descriptions, plus users’ own data types, now supplement the simple scalar and waveform types of the former EPICS. New computational architectures for scientific computing have been added for high-performance data processing services and pipelining. Python and Java bindings have enabled powerful new user interfaces. The result has been that controls are now being integrated with modelling and simulation, machine learning, enterprise databases, and experiment DAQs. We introduce this new EPICS (version 7) from the perspective of accelerator physics and review early adoption cases in accelerators around the world

Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification

In the REAL classification the diffuse large B-cell non-Hodgkin lymphomas (NHL) are grouped together, because subclassifications are considered to lack both reproducibility and clinical significance. Others, however, claim that patients with an immunoblastic NHL have a worse prognosis than patients with other types of diffuse large B-cell NHL. Therefore, we investigated the prognostic and clinical significance of histological subclassification of diffuse large B-cell NHL in a uniformly treated series of patients. For this retrospective study, all patients diagnosed as having an immunoblastic (IB) B-cell NHL by the Lymphoma Review Panel of the Comprehensive Cancer Center Amsterdam (CCCA) between 1984 and 1994, and treated according to the guidelines of the CCCA, were analysed. Patients with a centroblastic polymorphic subtype (CB-Poly) or centroblastic (CB) NHL by the Lymphoma Review Panel who were treated in the Netherlands Cancer Institute during the same period according to CCCA guidelines were used as reference groups. All patients' records were reviewed. Clinical parameters at presentation, kind of therapy and clinical outcome were recorded. All available histological slides were separately reviewed by two haemato-pathologists. One hundred and seventy-seven patients were included in the study: 36 patients (20.3%) with an IB NHL, 69 patients (39%) with a CB-Poly NHL and 72 patients (40.7%) with a CB NHL. The patients with an IB NHL tended to be older and presented more often with stage I or II and one extranodal site than patients with a CB and CB-Poly NHL. None of the subtypes showed a clear preference for localization in a particular site. The patients with IB or CB-Poly NHL showed a significantly worse prognosis than patients with CB NHL, with a 5-year overall survival for patients with CB NHL of 56.3% and for patients with IB or CB-Poly NHL 39.1% and 41.6% respectively. The 5-year disease free survival was 53.2% for the patients with CB, 32% for the patients with CB-Poly and 26.9% for the patients with IB NHL. A multivariate analysis showed that histological subtyping was of prognostic significance independent of the International Prognostic Index. This finding merits further exploration in prospective studies in order to judge the value of subclassification of large B-cell NHL as a guideline in therapy choice. © 1999 Cancer Research Campaig

NSLS-II Beam Diagnostics Overview

A new 3rd generation light source (NSLS-II) is in the early stages of construction at Brookhaven National Laboratory. The NSLS-II facility will provide ultra high brightness and flux with exceptional beam stability. It presents several challenges for diagnostics and instrumentation, related to the extremely small emittance. In this paper, we present an overview of all planned instrumentation systems, results from research and development activities; and then focus on other challenging aspects

Trachoma Prevalence and Associated Risk Factors in The Gambia and Tanzania: Baseline Results of a Cluster Randomised Controlled Trial

Trachoma is caused by Chlamydia trachomatis and is the leading infectious cause of blindness. The World Health Organization's (WHO) control strategy includes antibiotic treatment of all community members, facial cleanliness, and environmental improvements. By determining how prevalent trachoma is, decisions can be made whether control activities need to be put in place. Knowing what factors make people more at risk of having trachoma can help target trachoma control efforts to those most at risk. We looked at the prevalence of active trachoma and C. trachomatis infection in the eyes of children aged 0–5 years in The Gambia and Tanzania. We also measured risk factors associated with having active trachoma or infection. The prevalence of both active trachoma and infection was lower in The Gambia (6.7% and 0.8%, respectively) than in Tanzania (32.3% and 21.9%, respectively). Risk factors for active trachoma were similar in the two countries. For infection, the risk factors in Tanzania were similar to those for TF, whereas in The Gambia, only ocular discharge was associated with infection. These results show that although the prevalence of active trachoma and infection is very different between the two countries, the risk factors for active trachoma are similar but those for infection are different

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Background Neoadjuvant chemotherapy (NACT) for early breast cancer can make breast-conserving surgery more feasible and might be more likely to eradicate micrometastatic disease than might the same chemotherapy given after surgery. We investigated the long-term benefits and risks of NACT and the influence of tumour characteristics on outcome with a collaborative meta-analysis of individual patient data from relevant randomised trials. Methods We obtained information about prerandomisation tumour characteristics, clinical tumour response, surgery, recurrence, and mortality for 4756 women in ten randomised trials in early breast cancer that began before 2005 and compared NACT with the same chemotherapy given postoperatively. Primary outcomes were tumour response, extent of local therapy, local and distant recurrence, breast cancer death, and overall mortality. Analyses by intention-to-treat used standard regression (for response and frequency of breast-conserving therapy) and log-rank methods (for recurrence and mortality). Findings Patients entered the trials from 1983 to 2002 and median follow-up was 9 years (IQR 5–14), with the last follow-up in 2013. Most chemotherapy was anthracycline based (3838 [81%] of 4756 women). More than two thirds (1349 [69%] of 1947) of women allocated NACT had a complete or partial clinical response. Patients allocated NACT had an increased frequency of breast-conserving therapy (1504 [65%] of 2320 treated with NACT vs 1135 [49%] of 2318 treated with adjuvant chemotherapy). NACT was associated with more frequent local recurrence than was adjuvant chemotherapy: the 15 year local recurrence was 21·4% for NACT versus 15·9% for adjuvant chemotherapy (5·5% increase [95% CI 2·4–8·6]; rate ratio 1·37 [95% CI 1·17–1·61]; p=0·0001). No significant difference between NACT and adjuvant chemotherapy was noted for distant recurrence (15 year risk 38·2% for NACT vs 38·0% for adjuvant chemotherapy; rate ratio 1·02 [95% CI 0·92–1·14]; p=0·66), breast cancer mortality (34·4% vs 33·7%; 1·06 [0·95–1·18]; p=0·31), or death from any cause (40·9% vs 41·2%; 1·04 [0·94–1·15]; p=0·45). Interpretation Tumours downsized by NACT might have higher local recurrence after breast-conserving therapy than might tumours of the same dimensions in women who have not received NACT. Strategies to mitigate the increased local recurrence after breast-conserving therapy in tumours downsized by NACT should be considered—eg, careful tumour localisation, detailed pathological assessment, and appropriate radiotherapy

Adding Flexible Subscription Options to EPICS

The need for a mechanism to control and filter subscriptions to control system variables by the client was described in a paper at the ICALEPCS2009 conference [1]. The implementation follows a plug in design that allows the insertion of plug in instances into the event stream on the server side. The client can instantiate and configure these plug ins when opening a subscription, by adding modifiers to the channel name using JSON notation [2]. This paper describes the design and implementation of a modular server side plug in framework for Channel Access, and shows examples for plug ins as well as their use within an EPICS control syste